The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMoleculin Biotech, Inc. (Nasdaq: MBRX) announced positive preliminary blinded data from its Phase 2B/3 MIRACLE trial evaluating Annamycin for the treatment of Acute Myeloid Leukemia (AML). The trial recorded a 40% preliminary Complete Remission (CRc) rate among patients with relapsed or refractory AML. These results represent a significant 67% improvement compared to the historical response rates of cytarabine, a current standard of care. Crucially, the company confirmed that Annamycin continues to show an absence of cardiotoxicity, addressing a major safety concern in leukemia treatments. Moleculin remains on track to reach its next major milestone, with data unblinding scheduled for the first quarter of 2026. This clinical progress positions the company to potentially establish Annamycin as a superior and safer alternative for patients who have failed previous treatment regimens.